- Viatris ( NASDAQ: VTRS ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open.
- The consensus EPS Estimate is $0.83 (-15.3% Y/Y) and the consensus Revenue Estimate is $4.18B (-8.7% Y/Y).
- Over the last 1 year, VTRS has beaten EPS estimates 100% of the time and has beaten revenue estimates 50% of the time.
- Over the last 3 months, EPS estimates have seen 1 upward revision and 8 downward. Revenue estimates have seen 0 upward revisions and 7 downward.
- In Q1 , Viatris reiterated its previously issued guidance for 2022 including $17.0B-17.5B in revenue. ($ 17.02B consensus)
- Last quarter, Viatris shares have recorded the biggest intraday gain since January despite a slight topline miss posted by the generic drugmaker with its 1Q financials. While revenue from its key business segments dropped from the previous year, free cash flow and adjusted EBITDA exceeded Street forecasts.
- Also Read - Viatris initiated Sell at UBS on biosimilar exit
For further details see:
Viatris Q2 2022 Earnings Preview